Colorectal Carcinoma | irinotecan | Fluorouracil Infusion | Combined Modality Therapy | Leucovorin | FOLFIRI | bevacizumab | cetuximab
Item
patients with colorectal cancer receiving irinotecan in combination with infusional fluorouracil and leucovorin (folfri) with or without bevacizumab or irinotecan in combination with cetuximab
boolean
C0009402 (UMLS CUI [1])
C0123931 (UMLS CUI [2])
C0016360 (UMLS CUI [3,1])
C1827465 (UMLS CUI [3,2])
C0009429 (UMLS CUI [4])
C0023413 (UMLS CUI [5])
C1880658 (UMLS CUI [6])
C0796392 (UMLS CUI [7])
C0995188 (UMLS CUI [8])
Antiemetics | Chemotherapy
Item
all patients will receive the following standard antiemetic regimen prior to chemotherapy:
boolean
C0003297 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
Oral dexamethasone | Dexamethasone Intravenous
Item
dexamethasone 8 mg po/iv
boolean
C0360528 (UMLS CUI [1])
C0011777 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
5HT3 Receptor Antagonists | Ondansetron Intravenous Excluded | Oral dolasetron Excluded | Granisetron Intravenous Excluded | Oral granisetron Excluded | Palonosetron Intravenous Excluded | Palonosetron Oral Excluded
Item
an approved dose of a 5ht3 receptor antagonist. ondansetron 8mg iv or 24mg po dolasetron 100mg iv/po granisetron 1 mg iv or 2mg po use of palonosetron will be excluded on this trial no routine prophylaxis for delayed emesis will be given. patients will be instructed in the use of rescue antiemetics if needed.
boolean
C2917245 (UMLS CUI [1])
C0061851 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
C3214577 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
C0061863 (UMLS CUI [4,1])
C1522726 (UMLS CUI [4,2])
C2828389 (UMLS CUI [4,3])
C3211320 (UMLS CUI [5,1])
C2828389 (UMLS CUI [5,2])
C0220578 (UMLS CUI [6,1])
C1522726 (UMLS CUI [6,2])
C2828389 (UMLS CUI [6,3])
C0220578 (UMLS CUI [7,1])
C1527415 (UMLS CUI [7,2])
C2828389 (UMLS CUI [7,3])
Age
Item
minimum age of 18 years.
boolean
C0001779 (UMLS CUI [1])
Premenopausal state Serum pregnancy test negative | Premenopausal state Urine pregnancy test negative
Item
premenopausal patients must demonstrate a negative serum or urine pregnancy test prior to receiving chemotherapy.
boolean
C0232969 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C0232969 (UMLS CUI [2,1])
C0430057 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of 0-2 (appendix a)
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
execution of written informed consent
boolean
C0021430 (UMLS CUI [1])
Nausea Moderate | Nausea Severe | Vomiting | Prior Chemotherapy | Chemotherapy Irinotecan Based
Item
patients with history of moderate-severe nausea or any vomiting with prior chemotherapy including irinotecan based chemotherapy.
boolean
C0027497 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C0027497 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0042963 (UMLS CUI [3])
C1514457 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C0123931 (UMLS CUI [5,2])
C1705938 (UMLS CUI [5,3])
Antiemetics | Benzodiazepines chronic allowed
Item
concomitant use of any drug with potential antiemetic efficacy (appendix b) 24 hours before chemotherapy and during the 120 hour study period. chronic use (more than 2 weeks) of benzodiazepines is allowed.
boolean
C0003297 (UMLS CUI [1])
C0005064 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
Vomiting CTCAE Grades | Retching CTCAE Grades | Nausea CTCAE Grades
Item
vomiting, retching or nausea (nci > 1) in the 24 hours preceding chemotherapy
boolean
C0042963 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0232602 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
C0027497 (UMLS CUI [3,1])
C1516728 (UMLS CUI [3,2])
Palliative Surgery
Item
palliative surgery < 2 weeks from study entry
boolean
C0282282 (UMLS CUI [1])
Therapeutic radiology procedure
Item
concurrent radiotherapy
boolean
C1522449 (UMLS CUI [1])